A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Drug Resistance, Neoplasm
/ drug effects
Female
Follow-Up Studies
Humans
Ipilimumab
/ administration & dosage
Lymphoma, B-Cell
/ drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Prognosis
Rituximab
/ administration & dosage
Salvage Therapy
Survival Rate
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
04
02
2019
revised:
03
06
2019
accepted:
28
08
2019
pubmed:
5
9
2019
medline:
22
9
2020
entrez:
5
9
2019
Statut:
ppublish
Résumé
Based on the potential for ipilimumab (I) to augment T-cell activation, we hypothesize that ipilimumab would augment the efficacy of rituximab (R) in patients with relapsed/refractory (R/R) CD20 Thirty-three patients with R/R CD20 Toxicity was manageable; no dose-limiting toxicity was observed at the doses studied. When considering the entire cohort, efficacy was modest, with an objective response rate (ORR) of 24% and median progression-free survival (PFS) of 2.6 months. However, in follicular lymphoma patients, the ORR was 58% with a median PFS of 5.6 months. The randomized comparison of R with R+I demonstrated that R+I resulted in more effective B-cell depletion (BCD). Both B-cell depletion and the ratio of CD45RA The combination of R+I has manageable toxicity and encouraging efficacy in R/R follicular lymphoma. The ratio of CD45RA
Identifiants
pubmed: 31481504
pii: 1078-0432.CCR-19-0438
doi: 10.1158/1078-0432.CCR-19-0438
pmc: PMC7354236
mid: NIHMS1539041
doi:
Substances chimiques
Ipilimumab
0
Rituximab
4F4X42SYQ6
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7004-7013Subventions
Organisme : NCI NIH HHS
ID : P30 CA093373
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : NIH HHS
ID : DP2 OD008752
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA062505
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186717
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Blood. 2012 Jun 14;119(24):5688-96
pubmed: 22555974
Cancer Immunol Res. 2013 Jul;1(1):32-42
pubmed: 24777248
Nat Rev Immunol. 2016 Feb;16(2):90-101
pubmed: 26688349
Blood. 2012 Apr 19;119(16):3698-704
pubmed: 22389254
Ther Adv Hematol. 2016 Aug;7(4):209-21
pubmed: 27493711
Science. 1995 Nov 10;270(5238):985-8
pubmed: 7481803
Cancer Res. 2014 Aug 15;74(16):4258-69
pubmed: 24906621
N Engl J Med. 2014 Mar 13;370(11):1008-18
pubmed: 24450858
Nat Commun. 2017 Dec 22;8(1):2256
pubmed: 29273790
Blood. 2005 Jan 15;105(2):489-95
pubmed: 15358617
Blood. 2006 Mar 15;107(6):2409-14
pubmed: 16304057
Lancet Oncol. 2014 Nov;15(12):1311-8
pubmed: 25439689
Br J Haematol. 2014 May;165(3):375-81
pubmed: 24606326
Immunity. 1997 Oct;7(4):445-50
pubmed: 9354465
Chin Clin Oncol. 2015 Mar;4(1):5
pubmed: 25841712
Clin Adv Hematol Oncol. 2008 Jun;6(6):437-45
pubmed: 18567989
Immunity. 1995 Nov;3(5):541-7
pubmed: 7584144
Lancet Oncol. 2016 Aug;17(8):1081-1093
pubmed: 27345636
Leuk Lymphoma. 2008 Jan;49(1):102-12
pubmed: 18203019
Clin Cancer Res. 2006 Dec 1;12(23):7046-53
pubmed: 17145827
Clin Cancer Res. 2009 Oct 15;15(20):6446-53
pubmed: 19808874
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5
pubmed: 25918390
Blood. 2018 Jan 11;131(2):182-190
pubmed: 29074501
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981